CTOs on the Move

Grace Assisted Living

www.graceseniorcommunity.com

 
Grace Assisted Living is a Nampa, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Central Connecticut Coast YMCA

Since 1859 the Central Connecticut Coast Y branches have served as community centers in the heart of the twenty-five towns we serve. Much of the Central Connecticut Coast Y’s work is supported by membership dues, program fees and grants, but central to...

Milestone Centers

Milestone Centers Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Milestone Centers Inc. is based in Pittsburgh, PA. You can find more information on Milestone Centers Inc. at www.aemhmr.org

NovoLogix(SM)

NovoLogix is a cutting-edge Medical Pharmacy Benefit Management company.

Fluence Analytics

Fluence Analytics is a leader in continuous analytics and process control solutions for the polymer and biopharmaceutical industries. The company offers two product lines, ACOMP and ARGEN. ACOMP is a polymer smart manufacturing system that generates ne...

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.